CD133+ anaplastic thyroid cancer cells initiate tumors in immunodeficient mice and are regulated by thyrotropin

PLoS ONE

Volumn 4, Issue 4, 2009, Pages

  Friedman, Susan ^a   Lu, Min ^a   Schultz, Atara ^a   Thomas, Dolly ^a   Lin, Reigh Yi ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD133 ANTIGEN; OCTAMER TRANSCRIPTION FACTOR 4; THYROTROPIN; THYROTROPIN RECEPTOR; GLYCOPROTEIN; LEUKOCYTE ANTIGEN; PEPTIDE;

ANAPLASTIC THYROID CANCER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CARCINOGENESIS; CELL POPULATION; CELL PROLIFERATION; CELL RENEWAL; COLONY FORMING CELL; CONTROLLED STUDY; FLOW CYTOMETRY; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; NONOBESE DIABETIC MOUSE; SCID MOUSE; SIGNAL TRANSDUCTION; THYROID CANCER; UPREGULATION; ANIMAL; CANCER STEM CELL; CANCER TRANSPLANTATION; DRUG EFFECT; HUMAN; IMMUNOPHENOTYPING; METHODOLOGY; MOUSE MUTANT; PATHOLOGY; THYROID TUMOR; TUMOR CELL LINE; XENOGRAFT;

MUS;

ANIMALS; ANTIGENS, CD; CELL LINE, TUMOR; CELL PROLIFERATION; GLYCOPROTEINS; HUMANS; IMMUNOPHENOTYPING; MICE; MICE, SCID; NEOPLASM TRANSPLANTATION; NEOPLASTIC STEM CELLS; PEPTIDES; THYROID NEOPLASMS; THYROTROPIN; TRANSPLANTATION, HETEROLOGOUS;

EID: 65549105435     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0005395     Document Type: Article

References (41)

1. Cancer facts and figures - 2008 ACS, Atlanta, Georgia, http://seer.cancer.gov/statfacts/html/thyro_print.html.
2. Davies L, Welch HG (2006) Increasing incidence of thyroid cancer in the United States, 1973-2002. Jama 295: 2164-2167.
3. Pierie JP, Muzikansky A, Gaz RD, Faquin WC, Ott MJ (2002) The effect of surgery and radiotherapy on outcome of anaplastic thyroid carcinoma. Ann Surg Oncol 9: 57-64.
4. Reya T, Morrison SJ, Clarke MF, Weissman IL (2001) Stem cells, cancer, and cancer stem cells. Nature 414: 105-111.
5. Hope KJ, Jin L, Dick JE (2004) Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity. Nat Immunol 5: 738-743.
6. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 100: 3983-3988.
7. Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, et al. (2003) Identification of a cancer stem cell in human brain tumors. Cancer Res 63: 5821-5828.
8. Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, et al. (2007) Identification and expansion of human colon-cancer-initiating cells. Nature 445: 111-115.
9. Monzani E, Facchetti F, Galmozzi E, Corsini E, Benetti A, et al. (2007) Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential. Eur J Cancer 43: 935-946.
10. Klein WM, Wu BP, Zhao S, Wu H, Klein-Szanto AJ, et al. (2007) Increased expression of stem cell markers in malignant melanoma. Mod Pathol 20: 102-107.
11. Dou J, Pan M, Wen P, Li Y, Tang Q, et al. (2007) Isolation and identification of cancer stem-like cells from murine melanoma cell lines. Cell Mol Immunol 4: 467-472.
12. Yin AH, Miraglia S, Zanjani ED, Almeida-Porada G, Ogawa M, et al. (1997) AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood 90: 5002-5012.
13. Miraglia S, Godfrey W, Yin AH, Atkins K, Warnke R, et al. (1997) A novel five-transmembrane hematopoietic stem cell antigen: isolation, characterization, and molecular cloning. Blood 90: 5013-5021.
14. Mizrak D, Brittan M, Alison MR (2008) CD133: molecule of the moment. J Pathol 214: 3-9.
15. Yin S, Li J, Hu C, Chen X, Yao M, et al. (2007) CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity. Int J Cancer 120: 1444-1450.
16. Rountree CB, Senadheera S, Mato JM, Crooks GM, Lu SC (2008) Expansion of liver cancer stem cells during aging in methionine adenosyltransferase 1A-deficient mice. Hepatology 47: 1288-1297.
17. Piccirillo SG, Vescovi AL (2006) Bone morphogenetic proteins regulate tumorigenicity in human glioblastoma stem cells. Ernst Schering Found Symp Proc 5: 59-81.
18. Piccirillo SG, Reynolds BA, Zanetti N, Lamorte G, Binda E, et al. (2006) Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells. Nature 444: 761-765.
19. Ma YH, Mentlein R, Knerlich F, Kruse ML, Mehdorn HM, et al. (2008) Expression of stem cell markers in human astrocytomas of different WHO grades. J Neurooncol 86: 31-45.
20. Katoh Y, Katoh M (2007) Comparative genomics on PROM1 gene encoding stem cell marker CD133. Int J Mol Med 19: 967-970.
21. Suetsugu A, Nagaki M, Aoki H, Motohashi T, Kunisada T, et al. (2006) Characterization of CD133+ hepatocellular carcinoma cells as cancer stem/ progenitor cells. Biochem Biophys Res Commun 351: 820-824.
22. Florek M, Haase M, Marzesco AM, Freund D, Ehninger G, et al. (2005) Prominin-1/CD133, a neural and hematopoietic stem cell marker, is expressed in adult human differentiated cells and certain types of kidney cancer. Cell Tissue Res 319: 15-26.
23. Ma S, Chan KW, Hu L, Lee TK, Wo JY, et al. (2007) Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology 132: 2542-2556.
24. Ferrandina G, Bonanno G, Pierelli L, Perillo A, Procoli A, et al. (2007) Expression of CD133-1 and CD133-2 in ovarian cancer. Int J Gynecol Cancer.
25. Zito G, Richiusa P, Bommarito A, Carissimi E, Russo L, et al. (2008) In vitro identification and characterization of CD133(pos) cancer stem-like cells in anaplastic thyroid carcinoma cell lines. PLoS ONE 3: e3544.
26. De Vita G, Bauer L, da Costa VM, De Felice M, Baratta MG, et al. (2005) Dose-dependent inhibition of thyroid differentiation by RAS oncogenes. Mol Endocrinol 19: 76-89.
27. Chen ST, Lin JD, Lin KH (2002) Characterization of a thyroid hormone-mediated short-loop feedback control of TSH receptor gene in an anaplastic human thyroid cancer cell line. J Endocrinol 175: 459-465.
28. Schuppert F, Deiters S, Rambusch E, Sierralta W, Dralle H, et al. (1996) TSH-receptor expression and human thyroid disease: relation to clinical, endocrine, and molecular thyroid parameters. Thyroid 6: 575-587.
29. Metaye T, Levillain P, Kraimps JL, Perdrisot R (2008) Immunohistochemical detection, regulation and antiproliferative function of G protein-coupled receptor kinase 2 in thyroid carcinomas. J Endocrinol.
30. Yano Y, Kamma H, Matsumoto H, Fujiwara M, Bando H, et al. (2007) Growth suppression of thyroid cancer cells by adenylcyclase activator. Oncol Rep 18: 441-445.
31. De Falco V, Guarino V, Avilla E, Castellone MD, Salerno P, et al. (2007) Biological role and potential therapeutic targeting of the chemokine receptor CXCR4 in undifferentiated thyroid cancer. Cancer Res 67: 11821-11829.
32. Hwang JH, Chung HK, Kim DW, Hwang ES, Suh JM, et al. (2003) CXC chemokine receptor 4 expression and function in human anaplastic thyroid cancer cells. J Clin Endocrinol Metab 88: 408-416.
33. Lin RY (2007) New insights into thyroid stem cells. Thyroid 17: 1019-1023.
34. Thomas D, Friedman S, Lin RY (2008) Thyroid stem cells: lessons from normal development and thyroid cancer. Endocr Relat Cancer 15: 51-58.
35. Schweppe RE, Klopper JP, Korch C, Pugazhenthi U, Benezra M, et al. (2008) Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. J Clin Endocrinol Metab 93: 4331-4341.
36. Shmelkov SV, Butler JM, Hooper AT, Hormigo A, Kushner J, et al. (2008) CD133 expression is not restricted to stem cells, and both CD133+ and CD133- metastatic colon cancer cells initiate tumors. J Clin Invest 118: 2111-2120.
37. Ahn SH, Henderson Y, Kang Y, Chattopadhyay C, Holton P, et al. (2008) An orthotopic model of papillary thyroid carcinoma in athymic nude mice. Arch Otolaryngol Head Neck Surg 134: 190-197.
38. van Staveren WC, Solis DW, Delys L, Duprez L, Andry G, et al. (2007) Human thyroid tumor cell lines derived from different tumor types present a common dedifferentiated phenotype. Cancer Res 67: 8113-8120.
39. Fagin JA, Matsuo K, Karmakar A, Chen DL, Tang SH, et al. (1993) High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. J Clin Invest 91: 179-184.
40. Fagin JA, Tang SH, Zeki K, Di Lauro R, Fusco A, et al. (1996) Reexpression of thyroid peroxidase in a derivative of an undifferentiated thyroid carcinoma cell line by introduction of wild-type p53. Cancer Res 56: 765-771.
41. Fiore L, Pollina LE, Fontanini G, Casalone R, Berlingieri MT, et al. (1997) Cytokine production by a new undifferentiated human thyroid carcinoma cell line, FB-1. J Clin Endocrinol Metab 82: 4094-4100.